iGEM 2022 — Team iiser-tirupati-india

{% extends "layout.html" %}
{% block title %}Notebook{% endblock %}
{% block lead %}Document the dates you worked on your project. This should be a detailed account of the work done each day for your project.{% endblock %}
{% block page\_content %}

#

#

![Entrepreneurship](https://static.igem.wiki/teams/4438/wiki/banner-images/labnotebook.png)

# LAB NOTEBOOK

Interlab

Protein Purification

SELEX

FASTmiR

Dual Aptamer

# PROTOCOLS

Plasmid IsolationCompetency and TransformationProtein PurificationSDS-PAGEResuspensionPCR AmplificationPCR CleanupEthanol PrecipitationSpeedVacFirst Cycle of SELEXIn-Vitro TranscriptionAgarose Gel ElectrophoresisNative PAGEUrea PAGE

{% endblock %}

{% extends "layout.html" %}
{% block title %}Engineering Success{% endblock %}
{% block lead %}Demonstrate engineering success in a part of your project by going through at least one iteration of the engineering design cycle.{% endblock %}
{% block page\_content %}

#

#

![EDUCATION](https://static.igem.wiki/teams/4438/wiki/banner-images/engineering-success.png)

# **INTRODUCTION**

The principles of engineering can be applied to solve synthetic biology problems. Once we identify the problem, our engineering cycle begins with **designing a solution** that seems feasible. In the **build** stage, we extend the idea and **check for the feasibility** of the solution. Next, we **test** if the solution we came up with will work. In this manner, we **learn** the improvements to be made, and the cycle continues.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/dump-presentation-1.png)

**Figure 1.** The Design-Build-Test-Learn (DBTL) cycle

Our project **‘AptaSteles’** stands as testimony to the cycle. At every phase, the project underwent multiple iterations of the Design-Build-Test-Learn (DBTL) cycle. Integrating expert opinions, we reformed our system to achieve a better result.

In this section, the following are highlighted.

1. **Biomarker identification and analysis:** After considering multiple factors like the source, ease of extraction, and reliability, it was decided that the **biomarkers from the blood, such as microRNAs (miRNAs), proteins, and hormones,** would be the best options for detection.
2. **miRNA detection**: Because the miRNA levels are very low, we included a procedure for amplification. After an extensive literature review, we settled on the **isothermal miRNA-Recombinase Polymerase Amplification (miRPA) technique to amplify miRNAs.** Subsequently, the **Fluorescent Aptamer Sensor for Tracking microRNAs** (FASTmiR) module was used for detection.
3. ****Protein and Hormone detection:** The concentrations of biomarker proteins and hormones are also very low. Therefore, the signal given by the aptamers should be amplified, and a **dual aptamer** approach was adopted for this purpose.**
4. **Kit Design:** As the detection system changed, so did the kit design, to accommodate them.  Finally, a **3D prototype** **of a microfluidic chip** was printed and tested. The optical components were then accordingly optimised.

# Modules

Module 1
Module 2
Module 3
Module 4

## **Module 1: Biomarker Analysis**

Initially, we identified that the gene **DENND1A** is overexpressed in PCOS cases. The **variant V2 mRNA** of the same is specific to PCOS and can be detected in urinary exosomes [1]. Considering this to be our biomarker, we progressed to a stage where we tried to build upon its detection mechanism. However, on interacting with the **iGEM 2021 team IISER-Tirupati\_India,** we realised that PCOS, being a syndrome, cannot be concluded based on one biomarker. So we started our search for several biomarkers from different sample sources.

**Aim:** Finding biomarkers from a given sample source.

## **First cycle:**

**Design:** Keeping DENND1A V2 as our basis, other biomarkers in urine were searched for. Literature review revealed the existence of **testosterone glucuronide and 11-α hydroxyprogesterone** in urine [2], which were known to indicate PCOS. According to **Dr** **Shunmathe K R,** the **estrogen forms’ E1 and E2 ratio: E2/E1** is also a biomarker used by medical professionals. These were hence chosen as the biomarkers and further worked upon.

**Build:** As details of the biomarkers were looked upon, it was found that DENND1A V2 was excreted out of the body, packed in **exosomes** (vesicles from cell membrane that carries cargo).

**Test:** Various mechanisms for the uptake and internalisation of the exosomes for the mRNAs to be detected were assessed. **Cell-penetrating peptides** **and cell wall remodelling** were a few of the options considered for the uptake of exosomes. Internalisation mechanisms involving the **expression of CD81 receptors**  were found suitable [3-5]. Since eukaryotic proteins were to be expressed and functionalised, the host organism chosen was **Pichia Pastoris**, a model yeast strain.

**Learn:** We learned that specific information about the exosomes and the markers expressed on them were required to internalise the same. However, there was not enough details about them. Also, the biomarkers chosen were not inclusive of all the symptoms. We selected the biomarkers that indicated the changes happening in the ovaries; however, they did not give much idea about the other metabolic disorders in the body. The chosen biomarkers could vary due to other factors like the consumption of birth control pills and the usage of steroids, to name a few. Thus they cannot determine specifically PCOS. Considering the complications of internalisation and the compromise on accuracy of the chosen biomarkers, we left the idea of detecting the given ones from urine, Thus, we moved on to the next cycle.

## **Second cycle:**

**Design:** The search for biomarkers continued. We got to know that many biomarkers in the blood are indicative of different symptoms associated with PCOS.  A meeting with **Dr Surbhi Singh** gave us an idea about the various symptoms considered clinically for diagnosing a person with PCOS. So the biomarkers were selected in accordance with that, along with the other potential biomarkers in consideration, to ensure the kit's specificity towards testing PCOS.

**Build: 10 potential biomarkers** were identified from the **blood.** The biomarkers class ranges from **microRNAs to proteins and hormones**. (Click [Blueprint](https://2022.igem.wiki/iiser-tirupati-india/blueprint) to check for the individual biomarkers). The biomarkers were selected so that many comorbidities associated with PCOS could be detected.

**Test:** The biomarkers were checked for their specificity and sensitivity toward PCOS from existing literature. We found the specificity and sensitivity values for the chosen biomarkers. It is observed that the biomarkers had relatively high sensitivity towards PCOS (Click [Blueprint](https://2022.igem.wiki/iiser-tirupati-india/blueprint) to check for the individual values). So with this data, **we successfully identified the biomarkers.** We quickly found that detecting these biomarkers could cover a range of associated comorbidities, thus serving our purpose.

**Learn:** We learned that the combinations of a few of our biomarkers yielded better results. So we envisaged a model to find the best combination of biomarkers. But **Dr Shibdas Banerjee** pointed out that we need our experimental results for the same. Due to time constraints and ethical issues, we could not proceed with it.

![](https://static.igem.wiki/teams/4438/wiki/biomarkers-assocoated-with-pcos.png)

**Figure 2**. The chosen biomarkers

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/module-1.png)

**Figure 3**. Summary of module 1

## **Module 2: miRNA detection**

Among the biomarkers to be detected, four of them were miRNAs. Since miRNAs are only 22-25 bases long, they could be unequivocally complementary to any sequence.  So the choice of a proper detection mechanism was tough. After consideration of the pros and cons of the different mechanisms for detecting miRNAs, it was found that the **toehold system** is the best suited for the project.

**Aim:** To find the technique for the detection of miRNAs

## **First cycle:**

**Design:** The usual detection technique used for mRNAs is **riboswitches.** We modified it to use microRNAs.

**Build:** A riboswitch circuit is shown in the diagram below. We mined the database for the miRNA sequences to build the genetic circuit. In this riboswitch, the trigger sequence is the miRNA, and the toehold is the antisense of the miRNA. The gene of interest is GFP or any other fluorescent protein.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/ribositches.png)

**Figure 4.** Representation of Riboswitch

**Test:** We tried validating the circuit by finding different factors like the length of the stem loop and the length of toehold  that could affect the protein production. So we checked how these could be done in our specific case with the miRNAs of interest.

**Learn:** As we were developing a point-of-care device, we learnt that the employment of protein-based detection could make our system less reliable due to the labile nature of proteins. The protein fluoresces only on maturation (post-translational modifications). This leads to a time lag for the fluorescence to appear. In a protein based detection system, degradation of the protein is inevitable, which hinders the accuracy of the output it can give. Since we aim to quantify the biomarkers, we learnt that the protein-based detection method is not ideal. So we tried to avoid adding translational machinery to our system.

## **Second cycle:**

**Design:** Moving away from protein based systems, the next option we discovered is aptamers (Click [Background](https://2022.igem.wiki/iiser-tirupati-india/background) to know more about aptamers). Aptamers offered many advantages over protein systems in terms of cost, adaptability, stability, and many others. So with aptamers as the basis, we looked for methods of detecting miRNAs. We came across **Fluorescent Aptamer Sensor for Tracking microRNAs (FASTmiR)** used in detecting miRNA 122 [12]. The FASTmiR is an RNA sequence that is an extension of aptamers. It utilises light-up aptamers and a complementary sequence of the miRNA of interest (Click [Blueprint](https://2022.igem.wiki/iiser-tirupati-india/blueprint) to know more about FASTmiR).

**Build:** We found the FASTmiR approach to be suitable for our system and extended it to our biomarkers. Before testing, it was necessary to know quantitatively the amount of miRNA found in the blood.

**Test**: There was no data about our specific biomarkers. However, it is known that the total concentration of miRNA in cells is about 10-12 M [13]. Based on basic estimates done using Ct values of the miRNAs, the concentration of miRNA was assumed to be in the range of 10-14 M.

We tried to model this system using rate law kinetics. A graph of the concentration of FASTmiR-dye complex formed as a function of the concentration of miRNA (that we calculated to be present in the blood) was plotted.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/fastmir-dbtl.png)

**Figure 5.** Graph from FASTmiR model

**Learn:** The graph shows that the time taken to reach an equilibrium concentration of the aptamer-dye complex is in the range of 1018 s. We could immediately infer that the reaction was happening very slowly. This inference matched the data we got from the calculation, proving that the miRNA level is too low to be detected by FASTmiR.

## **Third cycle:**

**Design:** From the previous cycle's results, we realised the need for an amplification technique to increase the concentration of the miRNA biomarkers. We explored **isothermal amplification techniques** as they should be incorporated into the kit.

**Build:** After an extensive literature survey and vigorous brainstorming, we settled on **miRNA Recombinase Polymerase Amplification(miRPA)**, inspired by the **iGEM 2018 team City of London, UK** (Click [Blueprint](https://2022.igem.wiki/iiser-tirupati-india/blueprint) to know more about miRPA) [14-15]**.**

**Test:** We developed a mathematical model to understand the system and find the concentration after amplification.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/mirpa-1.jpg)

**Figure 6.** Graph from miRPA model without looping

The graph clearly showed that there was a very minimal amplification happening. However, the fold change was maintained nearly as the initial fold change. Then, as **Dr Jatish Kumar** pointed out about chain kinetics, we accounted for the recycling of miRNA and duplexed miDNA and looping back into the system.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/mirpa-model.png)

**Figure 7.** Graph from miRPA model with looping

We succeeded in achieving a significant quantity of biomarkers in 30 minutes.

**Learn:**

As seen in the graph, the fold change is still maintained. Theoretically, it was hypothesised that the same would be reflected in the concentration of the FASTmiR-dye complex.

## **Fourth cycle:**

**Design:**

We wanted to test our hypothesis. So the DNA sequences were designed in the following manner. The light-up aptamer used was **modified Spinach,** an RNA light up aptamer. The sequence on transcription has a binding pocket that particularly binds to **DFHBI dye** (a fluorophore) and gives fluorescent output (Click [Model](https://2022.igem.wiki/iiser-tirupati-india/model) to know more about the designs).

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/82.png)

**Figure 8.** Design of FASTmiR with terminator

**Build:**

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/fastmir.png)

**Figure 9.** Graph from FASTmiR model with amplified product

A mathematical model was built to check the concentration of FASTmiR- dye complex formed with the input being the amplified miDNA (output from miRPA) (Click [Model](https://2022.igem.wiki/iiser-tirupati-india/model) to know more about the model). The fold change was reflected in the model.

**Test:**

While designing our sequences, we gained input from various people. We then tested those sequences and checked their functionality. We did PCR amplification for the sequences to see that we were getting multiple bands. It was inferred that due to the length increment with the T7 terminator, the primers may have had more chances of non-specific binding, due to which we got multiple bands.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/engineeringsuccees-fastmir-figure-10.png)

**Figure 10.** Test of FASTmiR-146a all designs. One can see multiple bands of varying lengths.

**Learn:**

We learnt that there should not be a terminator at the end. The presence of the terminator poses the risk of non-specific primer binding and non-specific/incorrect IVT product.

## **Fifth cycle:**

##

**Design:** Meanwhile, we ordered our sequence-specific reverse primers that would ideally remove the T7 terminator from transcription and increases the specific binding of primers, lowering the chances of getting multiple bands.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/untitled-11-removebg-preview.png)

**Figure 11.** Design of FASTmiR without terminator

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/untitled-2.png)

**Figure 12.** Gel showing fewer faint multiple bands with the new reverse primers

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/engineering-success/engineeringsuccess-fastmir-figure-13.png)

**Figure 13.** Successful IVT with desired band length showing the removal of T7 terminator.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/fastmir/fluorescence-mir-146-30min.png)

**Figure 14.** Fluorescence readout for miR-146a-D4 after 30 mins incubation.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/fastmir/fluorescence-mir-146-1hr.png)

**Figure 15.** Fluorescence readout for miR-146a-D4 after 1 hour incubation.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/fastmir/fluorescence-mir-222-30min.png)

**Figure 16.** Fluorescence readout for miR-222-D2 after 30 mins incubation.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/fastmir/fluorescence-mir-222-1hr.png)

**Figure 17.** Fluorescence readout for miR-222-D2 after 1 hour incubation.

The validated IVT product shows fluorescence that matches the expected modelled fold change.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/module2.png)

**Figure 18.** Summary of Module 2

## **Module 3: Protein and Hormone Detection**

**Aptamers** are used widely for different types of molecules ranging from small molecules to proteins. So we decided to use aptamers to detect proteins and hormones because of their versatility.

**Aim:** To find an appropriate detection mechanism using aptamers for proteins and hormones.

## First cycle:

**Design:** We reviewed the different ways aptamers are raised for a given ligand. There are methods like Systematic Evolution of Ligand by EXponential enrichment **(SELEX)**, De Novo Rapid In Vitro Evolution of RNA biosensors **(DRIVER)** and in silico methods using softwares like Making Aptamers Without SELEX **(MAWS)** developed by the **iGEM 2015 Team Heidelberg.**

**Build:** We searched for characterised DNA/RNA aptamers specific to the protein and hormone biomarkers.  DNA aptamers for Luteinizing Hormone, Testosterone, CRP were identified. However, two of the protein biomarkers, Prolidase and Irisin, do not have any well-characterised aptamers for them. So, the detection plan bifurcated into two:

1. For the ones where there are no aptamers, we would raise the aptamers through SELEX.
2. The ones we have aptamers for would be used for biomarker detection.

**Test:** We purified proteins Prolidase and Irisin for SELEX. We also consulted experts to find ways to optimise the SELEX protocol.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/prolidase-bulk-wiki-1.png)

**Figure 19.** Gel showing the elutes of Prolidase

**Learn:**  SELEX protocol could be optimised to reduce the number of cycles and the time between each cycle.

## **Second cycle:**

**Design:** We designed our SELEX experiments based on the lesson learnt from the previous cycle and expert advice.

**Build:** We made a standard protocol for **DNA selex** and developed an outline of experimental flow that needs to be followed.

**Test:**

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/selex-gel-1.png)

**Figure 20.** Gel image showing incorrect library

We tested to verify whether our received orders i.e, our library (79 nucleotides and the primers) are purified and of the desired size.

**Learn:** The DNA library we received was wrong.

## **Third cycle:**

**Design:**

Since the library we got was wrong and there was a time constraint to order it again. So we looked for ways by which we could come over it. Then we realised the existence of an **in-house DNA/RNA synthesiser.**

**Build:**

We synthesised our own library of sequences using the protocol we **standardised for ourselves.**

**Test :**

We tested if the obtained library is the one required by running it on 10% native gel.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/selex-gel-2.png)

**Figure 21.**Gel showing the correct synthesised library

From the results, it was verified that the library is right. Thus we successfully synthesised our library. However, due to time constraints, we could not move forward with SELEX.

## **Fourth cycle:**

**Design:**

For the other plan of detection, we came across the usage of **light-up aptamers** for visualising non-coding RNA in live cells (Click [Background](https://2022.igem.wiki/iiser-tirupati-india/background) to know more about light-up aptamers) [10]. The concept of light-up aptamers gave us the start to build the system.

**Build:**

This system was built in parallel to SELEX using the already characterised aptamer.

The aptamers are fused with a light-up aptamer. When the target ligand of the aptamer binds to it, change in the conformation of the light up aptamer is induced. This leads to the binding of the dye to our aptamers, thus leading to fluorescence.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/picture-fluorescent-complex.png)

**Figure 22.**Fusion of light up aptamer and biomarker specific aptamer

**Test:**

The factors that affect the binding of the ligand to the aptamer were checked. It was found that truncating the extra regions of the aptamer, changing the distance of three-way regions, and many others could enhance the binding. We tried drawing comparisons to existing designs and testing the factors in our system.

**Learn:**

We realised that the biomarker concentration was too less to give a detectable fluorescent output. Quantifying the biomarkers based on such a low fluorescence output would be very difficult, and neither would it give a precise result.

## **Fifth cycle:**

**Design:** Since the fluorescence output was very low, there was some kind of amplification required. Unlike miRNAs which could be amplified before detection, for proteins and hormones, alternatively, the signal had to be amplified. Taking inspiration from [17], we devised **the dual aptamer approach.**

**Build:** The biomarker-specific aptamer has a trigger sequence bound to it. On binding of the biomarker, a conformational change is observed, which releases the trigger. The trigger sequence binds to the target sequence, which linearises and exposes the gene coding for light-up aptamers. This leads to the transcription of light-up aptamer which binds to the dye giving rise to a fluorescence complex (Click [Blueprint](https://2022.igem.wiki/iiser-tirupati-india/blueprint) for more information about the approach).

**Test:**  We designed the aptamer-trigger complex for 2 of the selected biomarkers (Testosterone and C-reactive proteins and 2 other biomolecules (Progesterone and Quinine) that could help us achieve our proof-of-concept. We built a mathematical model to understand the formation of the light-up aptamer complex. (Click [Model](https://2022.igem.wiki/iiser-tirupati-india/model) for more information about the designs and the model)

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/hs-crp.png)

**Figure 23.** Graph from dual aptamer model for hs-CRP

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/testosterone.png)

**Figure 24.** Graph from dual aptamer model for testesterone

**Learn:** We understood the working of the system and found that the light up aptamer reached an equilibrium after 3.5 hours. We went about testing the sequences experimentally.

## **Sixth cycle:**

**Design:** After the conceptual designing of the system, we designed two dual aptamer approaches to detect proteins and hormones.

1. Approach 1: With phi29 DNA polymerase
2. Approach 2:  Without phi29 DNA polymerase

Each dual aptamer system consists of biomarker-specific aptamer, trigger and target. The system is based on the release of triggers from the aptamer upon biomarker binding to the aptamer. This trigger release ultimately leads to the amplification of the signal by transcription of the light-up aptamer, Broccoli. The amount of biomarker is correlated with the fluorescence intensity of Broccoli at a given point in time.

**Build:** Using in-silico tools like NUPACK, Unafold, DuplexFold and analysing the thermodynamical parameters of the aptamers, we made the pipeline that followed to design of these triggers. (CLick [Model](https://2022.igem.wiki/iiser-tirupati-india/model) to know more). We designed multiple triggers for a given aptamer. For each biomarker, we made 3-7 trigger designs of varied lengths.

**Test:** Upon experimentally testing various designs for each approach, we realised that using approach 2 (without phi29 DNA polymerase), the system failed to detect any hormonal concentration, while approach 1 (with phi29 DNA polymerase) was successful in detecting the hormone at a given concentration.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-design/blocker-binder-flowchart.png)

**Figure 25.** Workflow to test our designs for approach 1

Our experiments showed promising results for the testosterone dual aptamer system

1. Incubation of testosterone with T6-D3

   ![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/t6-d3-ivt-results.png)

   **Figure 26.** Fluorescence readout for T6-D3 at various concentrations of Testesterone

   The above figure indicates that the concentration of testosterone has no effect on the fluorescence readout.
2. Incubation of testosterone with T6-D1 and D2

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/t6-d1-2-ivt-results.png)

**Figure 27.** Fluorescence readout for T6-D1 and D2

The above figure clearly shows that for D2 (Design 2) for the testosterone aptamer, the system was able to sense 1mM of testosterone and give a significant fluorescence readout which is 4 folds higher than the control (no hormone).

|  |  |
| --- | --- |
| Part number | Part name |
| [BBa\_K4438600](http://parts.igem.org/Part%3ABBa_K4438600) | Aptamer\_T6 |
| [BBa\_K4438603](http://parts.igem.org/Part%3ABBa_K4438603) | T6\_trigger\_2\_phi29 |
| [BBa\_K4438604](http://parts.igem.org/Part%3ABBa_K4438604) | T6\_Target\_2 |

We also tested all designs for progesterone and quinine aptamers, but we could not identify a working design. However, the design for T6-D2 would be a successful template for optimisations of designs in the future.

**Learn:**

From testing of all the plethora of designs, we realised the following learnings:

1. Complementarity between trigger and aptamer plays a very crucial role in both annealings of trigger-aptamer and release of trigger upon biomarker binding to aptamer.
2. Optimisation of aptamer-trigger concentrations could help increase the sensitivity of the system.
3. A one-pot reaction for Approach 2 (Without phi29) is not achievable due to the higher affinity of the trigger to the target. Hence, Approach 2 could be more prone to failure.

This led to optimisations in our kit design.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/module3.png)

**Figure 28.** Summary of Module 3

**(Comment after the competition) NOTE:**

* ****After troubleshooting our results, we realised that “Approach 1” wouldn’t be feasible due to the incorrect polarity of the sequences. In theory, this approach is not possible.****

* **We realised that “Approach 2” is the only feasible solution and this approach could be modified to detect proteins and hormones involving phi 29 DNA polymerase.**

* **The suggested modifications in “Approach 2” are:**

1. **Design the trigger sequence (removing sense T7 promoter sequence at 3’ end) complementary to an arbitrary sequence of the biomarker-specific aptamer.**
2. **The trigger sequence can have a few bases complementary to the antisense T7 promoter sequence at the 3’ end. Sequentially added phi 29 polymerases (after strand displacement) will form a double-stranded DNA promoter to initiate the transcription by T7 RNA polymerase.**
3. **Parameters like free energy of binding and secondary structures of all possible trigger-target sequences and trigger-aptamers sequences should be verified. This is necessary in order to maintain the specificity of binding in the presence and absence of the protein/hormone/ligand.**

## **Module 4A: Kit design**

Since our project was about making a diagnostic kit, we felt it was incomplete without the development of hardware. We immediately realised the potential of microfluidics. Thus we went about building a device based on the principles of microfluidics. We changed our designs to minimise the wastage of sample and to incorporate sequential addition of the reagents. To get a better picture of the iterations our kit design underwent, please check [Hardware](https://2022.igem.wiki/iiser-tirupati-india/hardware)

**Aim:** To optimise the microfluidic chip design and the components.

## **First cycle:**

**Design:**

Our microfluidic chip design underwent multiple iterations. With the help of Dr Dileep Mampallil, we came up with 7 designs (Click [Hardware](https://2022.igem.wiki/iiser-tirupati-india/model) to know more about the designs). Each design was an improved version of the previous one.

**Build:**

The designs were scrutinised based on the feasibility, ease of replication, and complexity. We then fixed two among them, one of them is the implemented kit and one to show a preliminary proof of concept.

![](https://static.igem.wiki/teams/4438/wiki/poc/dr-dileep-designgreynumbered.png)

**Figure 29.** Printed microfluidic Chip

![](https://static.igem.wiki/teams/4438/wiki/poc/before-fluorescense.jpg)

**Figure 30.a** Before Illumination

![](https://static.igem.wiki/teams/4438/wiki/poc/after-flurescence.jpg)

**Figure 30.b** After Illumination

**Test:**

We printed a mould of the design using a 3D printer and fabricated a Polydimethylsiloxane (PDMS) chip using it. The chip was made hydrophobic using teflon. It was tested with water.

The water from the storage chamber moves to the reaction chamber on gently pressing the storage chamber. Next we coated a new chip of the same design with silane (more hydrophobic). We tested the system with dye and broccoli light-up aptamer by adding them to the respective chambers. We successfully observed fluorescence on pressing the chamber containing the dye.

## **Module 4B: Signal Processing**

Since the output from our system is fluorescence, it was a necessity to have a proper sensing mechanism in place that could detect the fluorescence in the most accurate way.

## **First Cycle:**

**Design:**

Based on the requirements, the different components of the circuit were decided upon. One among them was the selection of the right mechanism for processing the signal. There were different options for the same.

1. Process the signal to give the electrical output to an Arduino board coded to give the digital output.
2. Convert the current output to voltage with a trans-impedance amplifier. The voltage output is then converted to digital output by an **analog-to-digital converter MCP3302/04 MCP3426/7/8** .
3. The current output is converted to digital output with a **DDC264/DDC316 Current-Input Analog-to-Digital Converter** ,which combines the current-to-voltage and A/D conversion.

In a discussion with Dr Kanagasekaran and Mr Sivaraju, we came to the conclusion that the first option might be the best way out.

**Build:**

We built the circuit in the following way to test the photodiodes and the Arduino's functionality.

![](https://static.igem.wiki/teams/4438/wiki/poc/prcessing-03.jpeg)

**Figure 31.** Circuit Setup and Validation

**Test:**

We developed the code for the Arduino.

Initially, we got either a “High” or “Low” display, which was dependent on the threshold. But it didn't change as we increased or decreased the light intensity value as expected.

Initial code:

<https://static.igem.wiki/teams/4438/wiki/engineering-success/initial-code-for-arduino-2.pdf>

Thus we changed the commands multiple times, and were successful in the end.

Final code which gave the result

<https://static.igem.wiki/teams/4438/wiki/engineering-success/final-code-for-arduino.pdf>

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/module-4.png)

**Figure 32.** Summary of Module 4

# REFERENCES

1. McAllister, J. M., Modi, B., Miller, B. A., Biegler, J., Bruggeman, R., & Legro, R. S. (2014). From the Cover: PNAS Plus: Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, *111*(15), E1519. <https://doi.org/10.1073/pnas.1400574111>
2. Wang, W., Wang, S., Tan, S., Wen, M., Qian, Y., Zeng, X., ... & Yu, C. (2015). Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS. *Clinica Chimica Acta*, *448*, 39-47.
3. ,Ruseska, I., & Zimmer, A. (2020). Internalization mechanisms of cell-penetrating peptides. *Beilstein journal of nanotechnology*, *11*, 101–123. <https://doi.org/10.3762/bjnano.11.10>
4. Rizzo, J., Rodrigues, M. L., & Janbon, G. (2020). Extracellular Vesicles in Fungi: Past, Present, and Future Perspectives. *Frontiers in Cellular and Infection Microbiology*. <https://doi.org/10.3389/fcimb.2020.00346>
5. Gurung, S., Perocheau, D., Touramanidou, L., & Baruteau, J. (2021). The exosome journey: From biogenesis to uptake and intracellular signalling. *Cell Communication and Signaling*, *19*(1), 1-19.
6. Bhatnager, R., Nanda, S., & Dang, A. S. (2018). Plasma prolidase levels as a biomarker for polycystic ovary syndrome. Biomarkers in Medicine, 12(6), 597-606.
7. Zhang, L., Fang, X., Li, L., Liu, R., Zhang, C., Liu, H., Tan, M., & Yang, G. (2018). The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. Journal of endocrinological investigation, 41(12), 1401–1407.
8. Sumithra, N. U., Lakshmi, R. L., Leela Menon, N., Subhakumari, K. N., & Sheejamol, V. S. (2015). Evaluation of Oxidative Stress and hsCRP in Polycystic Ovarian Syndrome in a Tertiary Care Hospital. Indian journal of clinical biochemistry : IJCB, 30(2), 161–166.
9. Abdelazim, I. A., Alanwar, A., AbuFaza, M., Amer, O. O., Bekmukhambetov, Y., Zhurabekova, G., Shikanova, S., & Karimova, B. (2020). Elevated and diagnostic androgens of polycystic ovary syndrome. Przeglad menopauzalny = Menopause review, 19(1), 1–5.
10. Sørensen, A. E., Wissing, M. L., Salö, S., Englund, A. L. M., & Dalgaard, L. T. (2014). MicroRNAs related to polycystic ovary syndrome (PCOS). Genes, 5(3), 684-708.
11. Long, W., Zhao, C., Ji, C., Ding, H., Cui, Y., Guo, X., ... & Liu, J. (2014). Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Cellular Physiology and Biochemistry, 33(5), 1304-1315.
12. Huang, K., Doyle, F., Wurz, Z. E., Tenenbaum, S. A., Hammond, R. K., Caplan, J. L., & Meyers, B. C. (2017). FASTmiR: an RNA-based sensor for in vitro quantification and live-cell localization of small RNAs. Nucleic acids research, 45(14), e130-e130.
13. Max, E. A., Bertram, K., Akat, K. M., Bogardus, K. A., Li, J., Morozov, P., Ben-Dov, I. Z., Li, X., Weiss, Z. R., Azizian, A., Sopeyin, A., Diacovo, T. G., Adamidi, C., Williams, Z., & Tuschl, T. (2018). Human plasma and serum extracellular small RNA reference profiles and their clinical utility. Proceedings of the National Academy of Sciences of the United States of America, 115(23), E5334. <https://doi.org/10.1073/pnas.1714397115>
14. [https://2021.igem.org/Team:City\_of\_London\_UK](https://2021.igem.org/Team%3ACity_of_London_UK)
15. Wee, E. J., & Trau, M. (2016). Simple isothermal strategy for multiplexed, rapid, sensitive, and accurate miRNA detection. Acs Sensors, 1(6), 670-675.
16. Paige, J. S., Nguyen-Duc, T., Song, W., & Jaffrey, S. R. (2012). Fluorescence imaging of cellular metabolites with RNA. *Science*, *335*(6073), 1194-1194.
17. Sheng, L., Lu, Y., Deng, S., Liao, X., Zhang, K., Ding, T., ... & Li, J. (2019). A transcription aptasensor: amplified, label-free and culture-independent detection of foodborne pathogens via light-up RNA aptamers. *Chemical Communications*, *55*(68), 10096-10099.
18. Namasivayam, V., Lin, R., Johnson, B., Brahmasandra, S., Razzacki, Z., Burke, D. T., & Burns, M. A. (2003). Advances in on-chip photodetection for applications in miniaturized genetic analysis systems. *Journal of Micromechanics and Microengineering*, *14*(1), 81.

{% endblock %}

{% extends "layout.html" %}
{% block title %}Experiments{% endblock %}
{% block lead %}Describe the research, experiments, and protocols you used in your iGEM project.{% endblock %}
{% block page\_content %}

#

# TEMPLATE PAGE

# Overview

Microfludic devices are explicitly designed to house, execute and test these circuits, fulfil specific
costs, performance and structural requirements.A crucial aspect in transforming needs into physical
objects is a disciplnied approach to the process so that it is a safe, effective and replicable.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Microfludic devices are explicitly designed to house, execute and test these circuits, fulfil specific
costs, performance and structural requirements.A crucial aspect in transforming needs into physical
objects is a disciplnied approach to the process so that it is a safe, effective and replicable.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Microfludic devices are explicitly designed to house, execute and test these circuits, fulfil specific
costs, performance and structural requirements.A crucial aspect in transforming needs into physical
objects is a disciplnied approach to the process so that it is a safe, effective and replicable.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Microfludic devices are explicitly designed to house, execute and test these circuits, fulfil specific
costs, performance and structural requirements.A crucial aspect in transforming needs into physical
objects is a disciplnied approach to the process so that it is a safe, effective and replicable.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

Needs must have requirements and solutions must quantifiably meet those needs. As engineering fields
mature, so do the engineering processes assoaciated with them.

{% endblock %}

{% extends "layout.html" %}
{% block title %}Results{% endblock %}
{% block lead %}You can describe the results of your project and your future plans here.{% endblock %}
{% block page\_content %}

#

#

![Entrepreneurship](https://static.igem.wiki/teams/4438/wiki/banner-images/results.png)

# OVERVIEW

This page documents the results for the experiments conducted towards achieving the proof of concept.

Characterization of FASTmiR
Characterization of Dual Aptamer
Protein Purification
SELEX
Interlab

## **Test PCR for FASTmiR-146a-D1**

**Aim** To optimise PCR conditions for Scale-Up PCR for FASTmiR-146a-D1

**Procedure** Prepared 15 μl reaction with varied concentrations of FASTmiR-146a-D1 template; 0 ng/μl, 2.5 ng/ μl, 5 ng/μl, 10 ng/μl.

**Results** Found 10 ng/μl to be the ideal concentration of the template.

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-gel-1.png)

**Figure 1.** Test PCR of FASTmiR-146a-D4.

**Labels** Lane 1: 100 bp DNA Ladder, Lane 2: 0 ng/μl negative control, Lane 3: 2.5 ng/μl template, Lane 4: 5 ng/μl template, Lane 5: 10 ng/μl

**Conclusion**After few trials, we found for the working concentration of 10 ng/μl of template the following PCR conditions

|  |  |
| --- | --- |
| Initial Denaturation: 2 mins |  |
| Denaturation Time: 6 secs | Denaturation Temperature: 98° C |
| Annealing Time: 10 secs | Annealing Temperature: 60°C |
| Extension Time: 6 secs | Extension Temperature: 72°C |
| Final Extension Time: 2 mins | Final Extension Temperature: 72°C |

## **Test PCR for FASTmiR-146a-D2 to D5**

**Aim** To test the **length** of FASTmiR-146a-D1, D2, D3, D4, D5 and optimise its **PCR** conditions.

**Result** Found the length of the designs to be approx. 200 to 210 bps.

**Conclusion** Expected length for the designs achieved.

**Results** Found 10 ng/μl to be the ideal concentration of the template.

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-gel-2.png)

**Figure 2.** Test PCR for all designs of FASTmiR-146a.

**Labels** Lane 1: 100 bps DNA ladder, Lane 2: 0 ng/μl template negative control, Lane 3: FASTmiR-146a-D1, Lane 4: FASTmiR-146a-D2, Lane 5: FASTmiR-146a-D3, Lane 6: FASTmiR-146a-D4, Lane 7: FASTmiR-146a-D5.

## **Test PCR for FASTmiR-27a and FASTmiR-30c Designs:**

**Aim** To test the lengths of our FASTmiR-27 and FASTmiR-30c designs

**Results** Found FASTmiR-27a-D1 and D2 to be approx. 190 bps and the rest loaded designs to be of expected length of approx. 140 bps.

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-gel-3-2.png)

**Figure 3.** Test PCR for all designs of FASTmiR-27a and FASTmiR-30c

**Labels** Lane 1: 100 bps DNA ladder, Lane 2: FASTmiR-27a-D1, Lane 3: FASTmiR-27a-D2, Lane 4: FASTmiR-27a-D3, Lane 5: FASTmiR-30c-D1, Lane 6: FASTmiR-30c-D2, Lane 7: FASTmiR-30c-D3.

## **IVT Confirmation for FASTmiR-146a**

**Aim** To check the expected length of the IVT product for FASTmiR-146a-D5

**Results** Found the IVT to be of expected length of 120bps.

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-gel-4-2.png)

**Figure 4.** IVT product for FASTmiR-146a-D5

**Labels** Lane 1: IVT product 3 μl loaded, Lane 2: IVT product 1 μl loaded, IVT product 0.5 μl loaded

## **Fluorescence Test of miR-146a-D4**

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-5-mod.png)

**Figure 5.**Fluorescence readout for miR-146a-D4 after 30 mins incubation.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Concentrations of DNA** | **1 μM** | **1.2 μM** | **1.4 μM** | **1.6 μM** | **1.8 μM** | **2 μM** |
| **C2 (Sensor Buffer+Dye+RNA)** | **999** | **1363** | **1925** | **7029** | **1579** | **6578** |
| **C3 (Sensor Buffer+Dye+RNA+DNA)** | **642** | **687** | **2859** | **4553** | **5241** | **9196** |
| **Fold Change** | **0.642** | **0.504** | **1.485** | **0.647** | **3.319** | **1.397** |

**Figure 6.** Table explaining the fold change for fluorescence readout for miR-146a-D4 after 30 mins incubation.

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-6.png)

**Figure 7.** Fluorescence readout for miR-146a-D4 after 1 hour incubation.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Concentrations of DNA** | **1 μM** | **1.2 μM** | **1.4 μM** | **1.6 μM** | **1.8 μM** | **2 μM** |
| **C2 (Sensor Buffer+Dye+RNA)** | **891** | **1261** | **1720** | **5215** | **1501** | **5448** |
| **C3 (Sensor Buffer+Dye+RNA+DNA)** | **619** | **643** | **2645** | **4171** | **4970** | **8766** |
| **Fold Change** | **0.694** | **0.509** | **1.537** | **0.799** | **3.311** | **1.609** |

**Figure 8.** Table explaining the fluorescence readout for miR-146a-D4 after 1 hour incubation.

## ****Fluorescence Test of miR-222-D2****

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-7.png)

**Figure 9.** Fluorescence readout for miR-222-D2 after 30 mins incubation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Concentrations of DNA** | **0.1 μM** | **0.25 μM** | **0.5 μM** | **1 μM** |
| **C2 (Sensor Buffer+Dye+RNA)** | **521** | **470** | **482** | **470** |
| **C3 (Sensor Buffer+Dye+RNA+DNA)** | **521** | **862** | **918** | **2843** |
| **Fold Change** | **1** | **1.834** | **1.904** | **6.048** |

![](https://static.igem.wiki/teams/4438/wiki/results-fastmir-gelimages/fastmir-results-8.png)

**Figure 11.** Fluorescence readout for miR-222-D2 after 1 hour incubation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Concentrations of DNA** | **0.1 μM** | **0.25 μM** | **0.5 μM** | **1 μM** |
| **C2 (Sensor Buffer+Dye+RNA)** | **537** | **451** | **539** | **449** |
| **C3 (Sensor Buffer+Dye+RNA+DNA)** | **496** | **890** | **1062** | **3333** |
| **Fold Change** | **0.923** | **1.973** | **1.970** | **7.423** |

[CLICK TO GO TO TOP](#Bar)

## **Testosterone Detection**

### Annealing of Trigger-Aptamer & Trigger-Target

**Aim** To confirm the annealing for the formation of trigger-T6 aptamer complex

**Procedure** Equimolar concentrations (50 μM) of trigger and aptamer for the trigger-aptamer complex in 1x TMS (Tris magnesium sulfate) buffer and DEPC-treated water.

**Results**:  Fig 1. indicates significant trigger-aptamer annealing for all three testosterone designs, as shown in lanes 5, 6, and 7. The shift in the size of bands on Native PAGE indicates the annealing of the single-strand sequence, as the binding of two strands would increase the complex's molecular weight.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig1da-results.png)

**Figure 1.** 16% Native PAGE: Annealing of Trigger- T6 Aptamer (D1-3)

**Label** Lane 1:Testosterone (T6) Aptamer; Lane 2: Trigger (First design); Lane 3:Trigger (Second design), Lane 4:Trigger (Third design); Lane 5:Aptamer + Trigger (First design); Lane 6: Aptamer + Trigger (Second design); Lane 7: Aptamer + Trigger (Third design)

##

### Testosterone Detection: Fluorescence Assay & In-vitro transcription of Broccoli

##

**Aim** To detect various concentrations of testosterone via fluorescence assay for Approach 2: dual aptamer without phi29 DNA polymerase (T6-design 3; T6-D3; Trigger-[BBa\_K4438605](https://2022.igem.wiki/iiser-tirupati-india/parts); Target-[BBa\_K4438606](https://2022.igem.wiki/iiser-tirupati-india/parts))

**Procedure** Incubate 10 μM of annealed trigger-T6 aptamer (D3) with 0 μM, 1 μM, 10 μM, and 100 μM of ethanol-dissolved testosterone propionate in 1x binding buffer and 1 μM target-design 3, at 25℃ celsius for 1 hour.

This is followed by in-vitro transcription by T7 RNA polymerase of the target strand to produce Broccoli aptamer for different testosterone concentrations.

**Results** For T6-D3, the fluorescence assay showed no significant difference in fluorescence at increasing testosterone concentrations. This indicates that the trigger has more affinity for the target than the aptamer due to the number of complementary sequences between them.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/t6-d3-ivt-results.png)

**Figure 2.** Fluorescence readout for T6-D3 at various concentrations of testosterone

**Comment**  Here, we realized that the range of concentration for the biomarker is too narrow for the first trials. Hence, we used higher concentrations for the test of further designs.

**Aim** To detect various concentrations of testosterone via fluorescence assay for Approach 1: dual aptamer with phi29 DNA polymerase. (T6-Design 1; T6-D1; Trigger-BBa\_K4438601; Target-[BBa\_K4438602](https://2022.igem.wiki/iiser-tirupati-india/parts) and T6-Design 2; T6-D2; Trigger-[BBa\_K4438603](https://2022.igem.wiki/iiser-tirupati-india/parts); Target-[BBa\_K4438604](https://2022.igem.wiki/iiser-tirupati-india/parts))

**Procedure**

Incubate 10 μM of annealed trigger-T6 aptamer (D1 and 2) with 0 μM, 10 μM, 100 μM, and 1 mM of ethanol-dissolved testosterone propionate in 1x binding buffer and 1 μM target-design 3, at 25℃ celsius for 1 hour.

The hormone-incubated products are incubated with phi29 DNA polymerase for the extension of the 3’-5’ trigger strand to produce duplexed DNA. This step is crucial for in-vitro transcription to take place

This is followed by in-vitro transcription by T7 RNA polymerase of the target strand to produce Broccoli aptamer for different testosterone concentrations.

**Results**

1. T6-Design 1: The fluorescence readout (Fig 3) indicates that the fold change in the fluorescence is not significant. Hence, there is no significant detection of testosterone.
2. T6-Design 2: The fluorescence readout (Fig 3) indicates that the fold change in the fluorescence is **significant of 4 folds for 1mM of testosterone.** This result shows that T6-D3

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/t6-d1-2-ivt-results.png)

**Figure 3.** Fluorescence readout for T6-D 1 and 2 at various concentrations of testosterone

##

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Concentration of Testosterone** | **0 μM** | **10 μM** | **100 μM** | **1 mM** |
| **(Sensor Buffer+Dye)** | **311** | **311** | **311** | **311** |
| **(Sensor Buffer+Dye+Trigger1-T6+Target1)** | **358** | **348** | **451** | **421** |
| **Fold Change** | **1.15** | **1.11** | **1.45** | **1.35** |

**Figure 4**.  Table for fluorescence readout for T6-D1

##

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Concentration of Testosterone** | **0 μM** | **10 μM** | **100 μM** | **1 mM** |
| **(Sensor Buffer+Dye)** | **311** | **311** | **311** | **311** |
| **(Sensor Buffer+Dye+Trigger2-T6+Target2)** | **358** | **407** | **417** | **1314** |
| **Fold Change** | **1.15** | **1.30** | **1.34** | **4.23** |

**Figure 5.** Table for fluorescence readout for T6-D2

##

**Comment:** Although T6-D2 shows 4 fold increase in fluorescence and detect 1mM of Testosterone, we believe that the following optimizations can lead to higher sensitivity i.e detection of lower levels of testosterone:

1. T6 aptamer - Trigger 3 relative concentrations while annealing
2. Tweaking few bases of the trigger to allow release of trigger at lower concentrations

## **Progesterone Detection**

### Annealing of Trigger-Aptamer & Trigger-Target

**Aim** To confirm the annealing for the formation of trigger-P4G13 aptamer complex

**Procedure** Equimolar concentrations (50 μM) of trigger and aptamer for the trigger-aptamer complex in 1x TMS (Tris magnesium sulfate) buffer and DEPC-treated water.

**Results**  Fig 6, Lane 5 indicates the annealing of Trigger 4- P4G13 aptamer

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig6da-results.png)

**Figure 6.** 16% Native-PAGE: Annealed P4G13 aptamer-Trigger 4 and Trigger 4 - Target 4

**Label**: Lane 1: P4G13 Aptamer; Lane 2: Trigger (Fourth design); Lane 3: Target (Fourth design), Lane 4:Target + Trigger (Fourth design); Lane 5: Aptamer + Trigger (Fourth design)

Lane 5 shows annealing of trigger and aptamer.

### Verification of release for Trigger upon incubation with Progesterone

**Aim** To verify release of trigger upon incubation with Progesterone

**Procedure**

1. Incubate 10 μM of annealed trigger-P4G13 aptamer (Design 4) with 0 μM, 1 μM, 10 μM, and 100 μM of ethanol-dissolved progesterone in 1x binding buffer and 1 μM target-design 4, at 25℃ celsius for 1 hour.
2. Incubate 10 μM of annealed  trigger-P4G13 aptamer (Design 4) with 0 μM, 10 μM, 100 μM, and 1000 μM of ethanol-dissolved progesterone in 1x binding buffer and 1 μM target-design 4, at 25℃ celsius for 1 hour.

**Results**

From Fig7 and 8, we can observe that a fraction of Triggger 4 is unbound from the P4G13 aptamer, irrespective of  the concentration of Progesterone.

However, Fig 8 indicates that the binding of P4G13 aptamer and Progesterone increases upon increasing hormone concentration. We speculated the free triggers from here could increase the background fluorescence after in-vitro transcription.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig7da-results.png)

**Figure 7.** 16% Native -PAGE: Test for Trigger 4 release upon incubation with Progesterone

##

Lane 1:Trigger (Design 1); Lane 2: Progesterone Aptamer; Lane 3: Aptamer + Trigger (Progesterone= 0 μM), Lane 4: Aptamer + Trigger (Progesterone= 1 μM); Lane 5: Aptamer + Trigger (Progesterone= 10 μM); Lane 6:  Aptamer + Trigger (Progesterone= 100 μM)

### Incubation with different concentrations of Progesterone

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig8da-results.png)

**Figure 8.** 20% Native-PAGE:Test 2 for Trigger 4 release upon incubation with Progesterone

Lane 1: Size Standard (66 Nucleotides); Lane 2: Aptamer; Lane 3:Aptamer + Trigger , Lane 4:  Aptamer + Biomarker ( 10 μM); Lane 5:Aptamer + Biomarker ( 100 μM); Lane 6: Aptamer + Biomarker ( 1000 μM); Lane 7: Aptamer + Trigger + Biomarker (10 μM); Lane 8: Aptamer + Trigger + Biomarker (100 μM); Lane 9: Aptamer + Trigger + Biomarker (1000 μM)

### Verification of extension of DNA strand by phi 29 polymerase

**Aim:** To verify extension of annealed DNA stands by phi 29 polymerase

**Procedure**

1. For a reaction volume of 20ul, add 0.5 uL Phi29 polymerase, 5 uL annealed DNA, 2 uL dNTPs, 2 uL Bovine Serum Ablumin (BSA), 2 uL 10xphi29 polymerase buffer,8.5 uL autoclaved milliQ water in a PCR tube.
2. Incubate at 30 degrees celsius for 30 minutes and then 65 degrees for 10 min.
3. Verify using Native PAGE.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig9da-results.png)

**Figure 9.** 12% Native PAGE: Verification of Extension by phi29

Lane 1:Aptamer ; Lane 2:Trigger ; Lane 3:Aptamer + Trigger ; Lane 4: Aptamer + Biomarker (Biomarker= 1000 μM)  ; Lane 5:Aptamer + Trigger + Biomarker ( Biomarker= 1000 μM); Lane 6: Size Standard; Lane 7: Trigger; Lane 8: Trigger + Target (Control, without extension); Lane 9: Trigger + Target (with extension)

**Results**

Figure 9. indicatesthe extension of trigger4 and target4 by phi29 polymerase. However, as predicted we observed extension in 1000 μM concentration of progesterone,but unfortunately we could not visualise the triggers due to their length.

### Progesterone Detection: Fluorescence Assay & In-vitro transcription of Broccoli

**Aim** To detect various concentrations of progesterone via fluorescence assay for Approach 1: dual aptamer with phi29 DNA polymerase (P4G13-Design 4; P4G13-D4; Trigger-[BBa\_K4438707](https://2022.igem.wiki/iiser-tirupati-india/parts); Target-[BBa\_K4438708](https://2022.igem.wiki/iiser-tirupati-india/parts))

**Procedure**

Incubate 10 μM of annealed trigger-P4G13 aptamer (D4) with 0 μM, 10 uM, 100 μM, 1 mM and 10 mM  of ethanol-dissolved progesterone in 1x binding buffer and 1 μM target-design 3, at 25℃ celsius for 1 hour.

The hormone-incubated products are incubated with phi29 DNA polymerase for the extension of the 3’-5’ trigger strand to produce duplexed DNA. This step is crucial for in-vitro transcription to take place.

This is followed by in-vitro transcription by T7 RNA polymerase of the target strand to produce Broccoli aptamer for different testosterone concentrations.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/p4-d4-ivt1-results.png)

**Figure 10.** Fluorescence readout: P4G13-D4 - 1

**Results** No significant increase in fluorescence upon increasing concentration of progesterone. Hence, we understand that this design could potentially work only after optimising and trying variations of P4G13 Trigger 4.

**Aim** To test trigger- target interaction via in-vitro transcription and effect on various concentrations of trigger on fluorescence readout (P4G13-Design 4; P4G13-D4)

**Procedure**

Incubate 50 μM of target(D 4) with annealed with 10 μM, 20 μM, 30 μM, 40 μM and 50 mM trigger concentration in 1x TMS buffer for 1.5 hrs

The hormone-incubated products are incubated with phi29 DNA polymerase for the extension of the 3’-5’ trigger strand to produce duplexed DNA. This step is crucial for in-vitro transcription to take place.

This is followed by in-vitro transcription by T7 RNA polymerase of the target strand to produce Broccoli aptamer for different testosterone concentrations.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/p4-d4-ivt2-results.png)

**Figure 11.** Fluorescence readout: P4G13-D4 - 1

**Results** We observed slight increase in fluorescence upon changing trigger-target concentration ratio. Hence, we understand that this design could potentially work only after optimising and trying variations of P4G13 Trigger 4.

## **Quinine and C-Reactive Protein Detection**

### Annealing of Trigger-Aptamer

**Aim** To confirm the annealing for the formation of triggers-MN4 aptamer complex

**Procedure** Equimolar concentrations (50 μM) of trigger and aptamer for the trigger-aptamer complex in 1x TMS (Tris magnesium sulfate) buffer and DEPC-treated water.

**Results** Fig 12 indicates that Design 5 and 6  for MN4 aptamer did not show any significant annealing of MN4 aptamer-Trigger.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig13da-results.png)

**Figure 12.** 16% Native PAGE: MN4 -Trigger (5 and 6)

Lane 1:Aptamer ; Lane 2:Trigger (design 5) ; Lane 3:Target (DESIGN 5); Lane 4: Trigger +Aptamer (design 5) ; Lane 5:Target + Trigger (design 5); Lane 6: Aptamer; Lane 7: Trigger (design 6); Lane 8: Target (design 6); Lane 9: Target + Trigger (design 6); Lane 10: Trigger + Aptamer (design 6)

### Verification of release for trigger upon incubation with Quinine

**Aim** To verify release of trigger upon incubation with Quinine

**Procedure** Incubate 10 μM of annealed trigger-MN4 aptamer (D3) with 0 μM, 1 μM, 10 μM, and 100 μM of DMSO-dissolved quinine hemisulfate salt monohydrate in 1x binding buffer and 1 μM target-design 3, at 25℃ celsius for 1 hour.

**Results** Fig 13 indicates that there is no significant release of trigger 3 even at high concentration of quinine. Hence we speculate that this trigger/aptamer could be tweaked to detect this

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/dual-aptamer/fig12da-results.png)

**Figure 13.** 20% Native -PAGE: Annealing of MN4-Trigger 3

Lane 1:Size Standard (66 Nucleotides); Lane 2: Quinine Aptamer; Lane 3:Aptamer + Trigger , Lane 4:  Aptamer + Biomarker ( 10 μM); Lane 5:Aptamer + Biomarker ( 100 μM); Lane 6: Aptamer + Biomarker ( 1000 μM); Lane 7: Aptamer + Trigger + Biomarker (10 μM); Lane 8: Aptamer + Trigger + Biomarker (100 μM); Lane 9: Aptamer + Trigger + Biomarker (1000 μM);

Comments

1. None of our native-PAGE assays could indicate annealing of the trigger-aptamer. So we went back to our in-silico analysis and picked Design 3 to test its incubation with quinine and test one of our designs       due to limitations of time.
2. We could not test designs for C-reactive protein due to delay in delivery of the ordered protein.

## **Conclusion**

We understood that the method of combining in-silico and hit and trial experimental design involves high throughput and time consuming experiments. This applies especially for our dual aptamer approach.  However, in the limited time and lab resources we had access to, we were able to successfully characterize a design to **detect testosterone (T6; [BBa\_K4438600](https://2022.igem.wiki/iiser-tirupati-india/parts)) at 1mM concentration.** The experiments and designs can be easily optimized to improve the sensitivity further.

[CLICK TO GO TO TOP](#Bar)

## **Protein Purification**

### PROLIDASE

**Aim** To purify histidine-tagged prolidase from the Rosetta strain. There are no existing DNA aptamers, and prolidase is required to develop DNA aptamers against it using SELEX.

**Protein expression and purification**

First, we expressed the prolidase in 20 mL 2xYT (supplemented with 100 ug/mL ampicillin and 34 ug/mL chloramphenicol) before proceeding with the bulk.

Protein expression was induced with 1mM IPTG (link to protein purification protocol). After purification using Ni-NTA affinity chromatography, we ran SDS-PAGE to confirm the presence and purity of our protein of interest.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/p1.png)

**Figure 1.** Result of prolidase test purification. Samples from different purification steps were loaded on an SDS-PAGE gel. Lane 1: Flow-through after binding; Lane 2: Uninduced cell pellet; Lane 3: Induced cell pellet, Lane 4: Lysis supernatant; Lane 5: Lysis pellet; Lane 6: Flow-through after binding; Lane 7: Wash 0 (10mM imidazole); Lane 8: 10-315 kDa protein ladder; Lane 9: Elute (300 mM imidazole)and Lane 10: Wash 1 (50 mM imidazole)

Lane 9 shows a faint band between 51-70 kDa range which is our expected range as the molecular weight of prolidase is 54 kDa. This confirms the presence of prolidase in elute fraction.

Next, we proceeded with the 2L bulk culture. A similar protocol was followed for this. Given below is the SDS-PAGE gel image for washes and elute fractions.

![](https://static.igem.wiki/teams/4438/wiki/engineering-success/prolidase-bulk-wiki-1.png)

**Figure 2.** Result of prolidase bulk purification. Washes and different elute fractions were loaded on an SDS-PAGE gel. Lane 1 and 9: 10-315 kDa protein ladder; Lane 2: Wash 1 (50 mM imidazole); Lane 3: Wash 2 (120 mM imidazole); Lane 4-13 (except 9): Different elute fractions collected with elution buffer containing 300 mM imidazole. Dark and thick bands are observed in the samples between the expected molecular weight range (i.e. 51 to 70 kDa).

After concentrating and desalting the elute fractions, the nanodrop concentration obtained was 6.8295 mg/mL.

## IRISIN

**Aim** To purify histidine-tagged irisin from E.coli BL21(DE3) strain.

**Plasmid DNA isolation**

Isolation of the plasmid construct pET-15b-irisin.

Nanodrop concentration- 47.65 ng/μL.

**Preparation of competent cells and transformation:** The plasmid construct pET-15b-irisin was transformed into *Escherichia coli* BL21 (DE3) cells.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/transformation-1.png)

**Figure 3.**Right image: LB agar plate with ampicillin and no plasmid (Control); left image: Transformed BL21 (DE3) cells with plasmid construct pET-15b-irisin

**Protein expression and purification**

From the freshly transformed plate, we picked 6-7 colonies and inoculated 20 mL of LB medium with 100 ug/mL of ampicillin. We induced the expression of protein with 0.5 mM IPTG followed by cell lysis and purification with Ni-NTA column chromatography (link to protein purification protocol page)

We ran SDS-PAGE with different fractions of protein obtained to confirm the presence and purity of irisin.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/expression-1.png)

**Figure 4.** SDS-PAGE result of purification of irisin from the supernatant. Lane 1:10-315 kDa protein ladder; Lane 2: Uninduced cell pellet; Lane 3: Induced cell pellet, Lane 4: Lysis supernatant; Lane 5: Lysis pellet; Lane 6: Flow-through after binding; Lane 7: Wash 0 (10mM imidazole); Lane 8: Wash 1 (50 mM imidazole) and Lane 9: Elute (300 mM imidazole)

We observed a band between 10-26 kDa range in lanes 4, 6, 7, 8, and 9.

Conclusion Papers report different molecular weights of irisin. We suspect that the clear band obtained corresponds to irisin.

[CLICK TO GO TO TOP](#Bar)

## **SELEX**

## VERIFICATION OF THE ORDERED DNA LIBRARY AND THE PRIMERS

**Aim** To verify the ordered DNA library and primers for its length and purity

**Procedure** 5 μl of 10 μM samples loaded in 16% Urea page, run for 3 hours at 120 volts.

**Results** Found that the given sample of DNA Library is not of preferred length.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/selex-gel-1.png)

**Figure 1:** urea page. Labels: Lane 1: size standard 80 bases, Lane 2: DNA library , Lane 3: forward primer, Lane 4: reverse primer, Lane 5: size standard 20 bases

**Inference**

1. Although we order a DNA library of 79 nucleotides, we received a faulty sequence of approximately 20 nucleotides.
2. The library is not suitable to carry forward with incubation of protein.

### VERIFICATION OF THE SYNTHESISED DNA LIBRARY

**Aim** To verify the synthesized DNA library for its length and purity

**Procedure** 5 μl of 10 μM samples loaded in 16% Urea page, run for 3 hours at 120 volts.

**Results** Found that the given sample is of preferred length(79 neuleotides)

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/selex-gel-2.png)

**Figure 2.** Urea page gel, label: lane 3: DNA Library (synthesized), lane 4: size standard 80 bases

**Inference**

The synthesised library is pure and is at the correct position with respect to the size standard.

### PCR BASED VERIFICATION OF THE SYNTHESIZED LIBRARY

**Aim** to amplify and verify the primers and the library

**Procedure**

1.5 μl of the synthesized DNA library was mixed in a 25 μl PCR reaction. 5 μl of 10 times diluted PCR sample was loaded into 10% native page for verification.

Gel was run for 60 minutes at 120 volts.

**Results** the PCR amplification works well with given library and the set of primers.

![](https://static.igem.wiki/teams/4438/wiki/wetlab-results/gel-3-selex.png)

**Figure 3:** the 10% native page for verification of PCR product. Labels: Lane 1: negative control 7 cycles, lane 2: positive control 7 cycles, lane 3: negative control 10 cycles,Lane 4: positive control 10 cycles, Lane 5: 100 base pair size standard

**Inference**

1. The library has the required sequences.
2. Primers function optimally.
3. The duplexed library can be used for incubation with protein followed by asymmetric PCR.

**Conclusion** The synthesized library is of good quality and can further be used.

[CLICK TO GO TO TOP](#Bar)

## **INTERLAB**

## Calibration of 96-well plate

**Aim**To calibrate the 96-well plate.

**Result** The calibration of the 96-well black-sided costar plate was done and the readout came out as attached. <https://static.igem.wiki/teams/4438/wiki/wetlab-results/interlab-calibration-iiser-tirupati-india-2022-sheet1.pdf>

Some of the wells had an absorbance that was greater than detectable by the instrument available to us. This could be because of the dilution error in the calibration protocol that was provided by the Engineering Committee during the initial phase, the protocol for which was later modified by them.

## Transformation of *Escherichia coli DH-5𝛼* with Test devices

Multiple attempts at transformation failed and the similar issue faced by different teams suggested a fault in the plasmid provided in the distribution kit.

We speculate that this could be because of

1. Plasmid-strain incompatibility
2. Low concentration of plasmids
3. Issues with the resuspension protocol provided

## Conclusion

Due to time constraints and the inability to devise a strategy around the allegedly defective plasmid, our experiments for the Interlab study were halted. Although we would have loved to complete the experiments.

[CLICK TO GO TO TOP](#Bar)

{% endblock %}